Cooperative Agreement UG3HL171357
Award Date
9/25/24
Completion Date
8/31/25
Dollars Obligated
$3.7M
Federal Agency
National Heart Lung and Blood Institute
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.837
Assistance Type
Cooperative Agreement
Place of Performance
Durham, NC 27710, USA
Similar Awards
The Duke University Office of Research Administration has been awarded a $1,220,496 Cooperative Agreement from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program. The purpose of this 5-year award is to conduct the U.S. portion of the multinational LEADER-PAD trial, which will assess the impact of low-dose colchicine on reducing cardiovascular and limb-related outcomes in patients with peripheral artery disease...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,529,292 Cooperative Agreement grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Northwestern University. The grant, titled "Improving Mobility After Revascularization in Peripheral Artery Disease: The IMPACT PAD Trial," will fund a 2-year randomized clinical trial to investigate the effects of home-based exercise and nitrate-rich beetroot juice on walking performance in patients with peripheral...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $528,179 to the University of Miami to conduct research focused on improving neovascularization in peripheral arterial disease (PAD) and critical limb ischemia (CLI). The key objectives of this research are to: 1) investigate the systemic effect of ischemia training on the reprogramming of bone marrow-derived monocytes, 2) determine if...
This $761,042 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of Pittsburgh to investigate the mechanisms driving medial arterial calcification (MAC) in peripheral artery disease (PAD). The key objectives are to: Define how the DNA damage response suppresses levels of the CD73 enzyme, which normally produces the anti-calcification molecule adenosine. Determine how reduced adenosine...
This federal Cooperative Agreement award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837), supports the Wake Forest University School of Medicine (WFUSM) as the Data Coordinating Center (DCC) for the Improving Mobility After Revascularization in Peripheral Artery Disease: The IMPACT PAD Trial (IMPACT PAD). The $1,398,792 award, with a period of performance from September 17, 2024 to August 31, 2031, will enable...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $660,200 Project Grant under the Cardiovascular Diseases Research Program (CFDA 93.837) to the University of Louisville to investigate the role of carnosine in treating peripheral arterial disease (PAD). The primary goal is to evaluate whether carnosine supplementation can improve lower extremity function in PAD patients. The university will conduct a pilot clinical trial and perform mechanistic studies to elucidate how carnosine...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund the development of a novel, contrast-free ultrasound-based technique called Angio Flow Reactivity Analysis (AFRA) to assess peripheral arterial disease (PAD) of the lower limbs. The $691,708 grant, awarded on August 1, 2024, will support a 5-year research project with the ultimate completion date of July 31, 2029. The project aims to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a $834,531 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant, which runs from January 1, 2025 to December 31, 2029, will fund research to investigate the effects of IL-1 beta inhibition on vascular inflammation in individuals with clonal hematopoiesis of indeterminate potential (CHIP), a...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $2,000,032 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Yale University. The 4-year grant, running from July 1, 2024 to April 30, 2028, supports research to determine how the LRP5 protein transports polyunsaturated fatty acids (PUFAs) and the importance of LRP5-transported PUFAs in regulating neutrophil activities and inflammation-related...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,172,434 Cooperative Agreement under the Cardiovascular Diseases Research program (CFDA 93.837) to the Research Triangle Institute (RTI International), a non-profit research organization. The purpose of this 5-year award is to design and implement a randomized, placebo-controlled clinical trial to evaluate the efficacy of the cardiovascular drug milrinone in preventing post-ligation cardiac syndrome, a serious complication...